8/29/23 16:08 | 8/25/23 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | P | 11 | 2.76 | 0 | 4 | 3 | 136 | D | | | | | | | | | | | | | | |
8/16/23 16:07 | 8/14/23 | CUE | Health | Drug | Pharmaceutical Preparations | Passeri Daniel R | MA | DO | CEO | P | 9 | 2.86 | 0 | 3 | 2 | 135 | D | | | | | | | | | | | | | | |
3/27/23 16:05 | 3/23/23 | CUE | Health | Drug | Pharmaceutical Preparations | Kiener Peter A | MA | D | | S.d | -31 | 3.28 | 0 | -9 | -96 | 0 | D | | | | | | | | | | | | | | |
3/27/23 16:05 | 3/23/23 | CUE | Health | Drug | Pharmaceutical Preparations | Kiener Peter A | MA | D | | M.d | 28 | 2.86 | 0 | 10 | | 0 | D | | | | | | | | | | | | | | |
8/23/22 16:03 | 8/21/22 | CUE | Health | Drug | Pharmaceutical Preparations | Millar Kerri-Ann | MA | O | CFO | M.d | 0 | 0.00 | 0 | 7 | 87 | 14 | D | | | | | | | | | | | | | | |
5/31/22 16:06 | 5/27/22 | CUE | Health | Drug | Pharmaceutical Preparations | Morich Frank | MA | D | | P | 105 | 3.75 | 0 | 28 | New | 28 | D | | | | | | | | | | | | | | |
5/25/22 09:09 | 5/23/22 | CUE | Health | Drug | Pharmaceutical Preparations | Fletcher Aaron G.L. | MA | D | | P.m | 712 | 3.47 | 0 | 205 | 23 | 1,114 | I | | | | | | | | | | | | | | |
4/4/22 17:31 | 3/31/22 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | M.d | 0 | 0.00 | 0 | 17 | 19 | 104 | D | | | | | | | | | | | | | | |
4/4/22 17:29 | 3/31/22 | CUE | Health | Drug | Pharmaceutical Preparations | Passeri Daniel R | MA | DO | CEO | M.d | 0 | 0.00 | 0 | 75 | 133 | 132 | D | | | | | | | | | | | | | | |
4/4/22 17:28 | 3/31/22 | CUE | Health | Drug | Pharmaceutical Preparations | Fletcher Aaron G.L. | MA | D | | P | 3,499 | 4.76 | 0 | 735 | 423 | 909 | I | | | | | | | | | | | | | | |
11/17/21 17:00 | 11/15/21 | CUE | Health | Drug | Pharmaceutical Preparations | Kiener Peter A | MA | D | | M.dm | 58 | 2.86 | 0 | 20 | | 0 | D | | | | | | | | | | | | | | |
11/17/21 17:00 | 11/15/21 | CUE | Health | Drug | Pharmaceutical Preparations | Kiener Peter A | MA | D | | S.dm | -362 | 17.93 | 0 | -20 | -100 | 0 | D | | | | | | | | | | | | | | |
11/17/21 17:00 | 11/15/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | S.d | -144 | 18.05 | 0 | -8 | -8 | 94 | D | | | | | | | | | | | | | | |
11/17/21 17:00 | 11/15/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | M.d | 66 | 8.26 | 0 | 8 | 9 | 94 | D | | | | | | | | | | | | | | |
11/15/21 17:00 | 11/11/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | S.d | -301 | 15.07 | 0 | -20 | -18 | 94 | D | | | | | | | | | | | | | | |
11/15/21 17:00 | 11/11/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | M.d | 128 | 6.42 | 0 | 20 | 27 | 94 | D | | | | | | | | | | | | | | |
10/8/21 16:00 | 9/30/21 | CUE | Health | Drug | Pharmaceutical Preparations | Passeri Daniel R | MA | DO | CEO | M.d | 0 | 0.00 | 0 | 75 | 316 | 99 | D | | | | | | | | | | | | | | |
10/8/21 16:00 | 10/3/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | M.d | 0 | 0.00 | 0 | 33 | 55 | 94 | D | | | | | | | | | | | | | | |
10/5/21 19:21 | 10/1/21 | CUE | Health | Drug | Pharmaceutical Preparations | Millar Kerri-Ann | MA | O | CFO | S.d | -18 | 14.21 | 0 | -1 | -11 | 10 | D | | | | | | | | | | | | | | |
10/5/21 19:21 | 8/23/21 | CUE | Health | Drug | Pharmaceutical Preparations | Millar Kerri-Ann | MA | O | CFO | M.dm | 9 | 1.18 | 0 | 8 | 310 | 10 | D | | | | | | | | | | | | | | |
9/27/21 16:30 | 9/23/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | S.d | -305 | 15.23 | 0 | -20 | -21 | 75 | D | | | | | | | | | | | | | | |
9/27/21 16:30 | 9/23/21 | CUE | Health | Drug | Pharmaceutical Preparations | Suri Anish | MA | O | P,CSO | M.d | 128 | 6.42 | 0 | 20 | 36 | 75 | D | | | | | | | | | | | | | | |
9/27/21 16:30 | 9/24/21 | CUE | Health | Drug | Pharmaceutical Preparations | Passeri Daniel R | MA | DO | CEO | P | 50 | 14.72 | 0 | 3 | 7 | 55 | D | | | | | | | | | | | | | | |